Retinoblastoma


Research findings from Baylor College of Medicine, College of Medicine update understanding of retinoblastoma in children



Retinoblastoma Library
Library Home

This article was published in Biotech Business Week, which you can subscribe to online.

2007 NOV 19 -- Scientists discuss in 'Retinoblastoma: review of current management' new findings in retinoblastoma. "The most common ocular cancer in children is retinoblastoma. It affects approximately 300 children in the U.S. every year," scientists in the United States report.

"It can affect one or both eyes and the disease can be inherited. Altered discoloration of the pupil and strabismus are the usual symptoms that lead to medical attention. Subsequent appropriate diagnostic studies and care provided by a multidisciplinary team, including an ophthalmologist, a pediatric oncologist, a radiation oncologist, and a geneticist, among others, often result in optimal short-term and long-term care. The best initial and subsequent treatments are based on whether the child has unilateral or bilateral disease, the stage of the disease, and the age of the child. Enucleation, chemotherapy, and various forms of radiation therapy along with local ophthalmic therapies can be used in the treatment of retinoblastoma. Cure rates are high in children when the tumor is confined to the eye and has not spread systemically or into the orbit or brain. Children with the heritable form of retinoblastoma are at high risk for developing subsequent malignancies, most commonly sarcomas. This risk is greater for those children with the heritable form of the disease who were exposed to ionizing radiation at age <1 year," wrote M. Chintagumpala and colleagues, Baylor College of Medicine, College of Medicine.

The researchers concluded: "Exciting discoveries using animal models are providing new insights into the development of this disease and opening new avenues for targeted therapies that may lead to high cure rates with minimal toxicities."

Chintagumpala and colleagues published their study in Oncologist (Retinoblastoma: review of current management. Oncologist, 2007;12(10):1237-46).

For more information, contact M. Chintagumpala, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas USA..

Publisher contact information for the journal Oncologist is: Alphamed Press, One Prestige Place, Ste. 290, Miamisburg, OH 45342-3758, USA.

Keywords: United States, Houston, Oncology, Ophthalmology, Retinoblastoma, Therapy, Treatment.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.